Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Preferred Stock Liabilities: 2012

  • Ptc Therapeutics' Preferred Stock Liabilities was N/A to $80.8 million in Q4 2012 from the same period last year, while for Dec 2012 it was $80.8 million, marking a year-over-year change of. This contributed to the annual value of $80.8 million for FY2012, which is 62.30% down from last year.
  • Latest data reveals that Ptc Therapeutics reported Preferred Stock Liabilities of $80.8 million as of Q4 2012.
  • In the past 5 years, Ptc Therapeutics' Preferred Stock Liabilities registered a high of $80.8 million during Q4 2012, and its lowest value of $80.8 million during Q4 2012.
  • Its 1-year average for Preferred Stock Liabilities is $80.8 million, with a median of $80.8 million in 2012.